Surgery Partners (SGRY) Form 144 — Option Exercise and Planned Sale Disclosed

Rhea-AI Filing Summary

Form 144 filed for Surgery Partners, Inc. (SGRY) proposing the sale of 11,865 common shares through UBS Financial Services on 08/27/2025. The shares were acquired on 08/27/2025 as equity compensation via an option exercise from Surgery Partners, Inc. The filing reports the issuer has 128,209,410 shares outstanding and lists the planned sale’s aggregate market value as $271,755. The notice also discloses prior dispositions by the same person in the past three months: 25,000 shares sold on 08/26/2025 for $535,339 and 100,000 shares sold on 08/21/2025 for $2,299,011. The filer represents no undisclosed material adverse information is known.

Positive

• Timely disclosure of proposed sale and recent transactions under Rule 144
• Transaction details provided (dates, amounts, broker, aggregate proceeds) enabling market transparency

Negative

• Insider liquidity activity disclosed: 125,000 shares sold in prior week could be viewed negatively by some investors
• Filer identification fields are blank in the provided content (no filer name/CIK shown), limiting traceability in this excerpt

Insights

Securities Analyst

TL;DR: Rule 144 notice shows an insider exercising options and disposing of shares; recent sales are disclosed and timely compliance is evident.

The filing documents a proposed sale of 11,865 common shares acquired the same day by equity compensation (option exercise) and scheduled to be sold via UBS on 08/27/2025. The filing also reports two recent sales totaling 125,000 shares in late August 2025 with combined gross proceeds of $2,834,350. These disclosures are routine for Section 16 filers using Rule 144 to effect sales of restricted or control securities and serve to notify the market of insider liquidity events. The filing contains basic transaction details and a representation that no material non‑public information is known to the seller.

Corporate Governance Expert

TL;DR: The notice is a standard compliance filing; it documents option exercise and immediate planned sale and confirms the seller's attestation regarding material information.

The submission indicates internal equity compensation (option exercise) followed by a planned disposition and discloses recent open‑market sales by the same individual. The form includes the seller’s attestation that no undisclosed material adverse information exists. From a governance perspective, the filing meets disclosure expectations for insider transactions but does not provide context on any trading plan or whether sales were part of a pre‑arranged plan.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	11865	271755	128209410	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/27/2025	Equity Compensation	Surgery Partners, Inc			11865	08/27/2025	Equity Option Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	535339
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Surgery Partners (SGRY) report?

The Form 144 reports a proposed sale of 11,865 common shares via UBS on 08/27/2025, acquired the same day by equity compensation (option exercise).

How many shares were sold by the same person in the past three months?

125,000 shares were reported sold in the past three months: 100,000 on 08/21/2025 (gross proceeds $2,299,011) and 25,000 on 08/26/2025 (gross proceeds $535,339).

What broker is handling the planned sale?

UBS Financial Services Inc. (1000 Harbor Blvd, Weehawken, NJ) is listed as the broker for the planned sale.

Were the 11,865 shares acquired via purchase or compensation?

Acquired via equity compensation on 08/27/2025 through an equity option exercise from Surgery Partners, Inc.

Does the filing state whether the seller knows any undisclosed material information?

Yes. The filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.